Abstract | OBJECTIVE: METHODS: A total of 57 patients with advanced kidney cancer were recruited from our hospital from April 2007 to October 2011. They were divided into sorafenib group (A, n = 24) and sorafenib + IFN group (B, n = 33). The primary endpoints included objective response rate and progression-free survival (PFS). And the secondary endpoints were overall survival (OS) and incidence of adverse events. RESULTS: The mean medication time of group A was 15 (7-56) months. The outcomes were partial response (PR, n = 1), stable disease (SD, n = 8), progressive disease (PD, n = 1) and death (n = 14). The rates of objective response and disease control were 4.2% (1/24) and 37.5% (9/24) respectively. For group B, the mean medication time was 15 (4-30) months. The outcomes were PR (n = 2), and include 2 patients of PR, 21 examples of SD, 1 patient of PD and death. The rates of objective response and disease control were 6.1% (2/33) and 69.7% (23/33) respectively. Two groups had no significant difference in incidence or severity of adverse events (both P > 0.05). CONCLUSIONS: As a safe and effective agent for advanced kidney cancer, sorafenib is well-tolerated in patients. The combined use of interferon may improve the therapeutic efficacies without an occurrence of adverse events.
|
Authors | Tao Huang, Xi-shuang Song, Zhi-wei Zhang |
Journal | Zhonghua yi xue za zhi
(Zhonghua Yi Xue Za Zhi)
Vol. 93
Issue 24
Pg. 1903-5
(Jun 25 2013)
ISSN: 0376-2491 [Print] China |
PMID | 24124745
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Phenylurea Compounds
- Niacinamide
- Interferons
- Sorafenib
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Female
- Humans
- Interferons
(administration & dosage)
- Kidney Neoplasms
(drug therapy)
- Male
- Middle Aged
- Niacinamide
(administration & dosage, analogs & derivatives)
- Phenylurea Compounds
(administration & dosage)
- Sorafenib
- Treatment Outcome
|